References
- Alkan G, Senturk Oztas N, Turna ZH, Ozguroglu M. 1168P Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. Ann Oncol. 2022; 33:S1082. https://doi.org/10.1016/j.annonc.2022.07.1291
- American Cancer Society. What causes lung cancer? [Internet]. Atlanta (USA): American Cancer Society, Inc.; 2019 [cited 2023 May 5]. Available from https://www.cancer.org/cancer/lung-cancer/causes-risks-prevention/what-causes.html
- Brawley OW, Glynn TJ, Khuri FR, Wender RC, Seffrin JR. The first Surgeon General’s report on smoking and health: the 50th anniversary. CA Cancer J Clin. 2014 Jan–Feb;64(1):5–8. https://doi.org/10.3322/caac.21210
- Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 Dec;358(6369):1443–1448. https://doi.org/10.1126/science.aal5240
- CDC. What are the risk factors for lung cancer? [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2023 [cited 2023 May 5]. Available from https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm
- Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG; im CORE working group of early career investigators. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020 Apr;31(4):525–531. https://doi.org/10.1016/j.annonc.2020.01.006
- Chang ET, Smedby KE, Hjalgrim H, Schöllkopf C, Porwit-Mac-Donald A, Sundström C, Tani E, d’Amore F, Melbye M, Adami HO, et al. Medication use and risk of non-Hodgkin’s lymphoma. Am J Epidemiol. 2005 Nov;162(10):965–974. https://doi.org/10.1093/aje/kwi311
- Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and nonsmall-cell lung cancer. Ann Oncol. 2018 Jun;29(6):1437–1444. https://doi.org/10.1093/annonc/mdy103
- Dickson RP, Huffnagle GB. The lung microbiome: New principles for respiratory bacteriology in health and disease. PLoS Pathog. 2015 Jul;11(7):e1004923. https://doi.org/10.1371/journal.ppat.1004923
- Didham RC, Reith DM, McConnell DW, Harrison KS. Antibiotic exposure and breast cancer in New Zealand. Breast Cancer Res Treat. 2005 Jul;92(2):163–167. https://doi.org/10.1007/s10549-005-2115-8
- ECIS. European Cancer Information System. Brussels (Belgium): European Union; 2023 [cited 2023 May 5]. Available from https://ecis.jrc.ec.europa.eu
- Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: A new independent prognostic factor? Ann Oncol. 2019 Oct;30(10):1572–1579. https://doi.org/10.1093/annonc/mdz206
- Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment – a nationwide populationbased study. Cancer Manag Res. 2019 Sep;11:8539–8546. https://doi.org/10.2147/CMAR.S222278
- Galli G, Poggi M, Fucà G, Imbimbo M, Proto C, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F, et al. Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer. Ann Oncol. 2018 Nov;29:viii531. https://doi.org/10.1093/annonc/mdy292.088
- Geum MJ, Kim C, Kang JE, Choi JH, Kim JS, Son ES, Lim SM, Rhie SJ. Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer. Pharmaceuticals. 2021 May;14(5):445. https://doi.org/10.3390/ph14050445
- Gonugunta AS, Von Itzstein MS, Hsiehchen D, Le T, Rashdan S, Yang H, Selby C, Alvarez C, Gerber DE. Antibiotic prescriptions in lung cancer and melanoma populations: Differences with potential clinical implications in the immunotherapy era. Clin Lung Cancer. 2023 Jan;24(1):11–17. https://doi.org/10.1016/j.cllc.2022.09.005
- Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018 Apr;33(4):570–580. https://doi.org/10.1016/j.ccell.2018.03.015
- Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007 May;1(1):56–66. https://doi.org/10.1038/ismej.2007.3
- Kilkkinen A, Rissanen H, Klaukka T, Pukkala E, Heliövaara M, Huovinen P, Männistö S, Aromaa A, Knekt P. Antibiotic use predicts an increased risk of cancer. Int J Cancer. 2008 Nov;123(9): 2152–2155. https://doi.org/10.1002/ijc.23622
- Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez--Outschoorn UE, Sotgia F, Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget. 2015 Mar;6(7):4569–4584. https://doi.org/10.18632/oncotarget.3174
- Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, et al. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: A strategy to promote immunosurveillance against lung metastases. Cell Rep. 2018 Sep;24(13):3528–3538. https://doi.org/10.1016/j.celrep.2018.08.090
- Lee SH, Sung JY, Yong D, Chun J, Kim SY, Song JH, Chung KS, Kim EY, Jung JY, Kang YA, et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer. 2016 Dec;102:89–95. https://doi.org/10.1016/j.lungcan.2016.10.016
- Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM, Qu JM. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int J Cancer. 2018 Feb; 142(4):769–778. https://doi.org/10.1002/ijc.31098
- Löfling L, Bahmanyar S, Kieler H, Lambe M, Wagenius G. Anti-biotic use prior to a lung cancer diagnosis: A population-based study. Cancer Causes Control. 2021 Jun;32(6):597–607. https://doi.org/10.1007/s10552-021-01413-5
- Löfmark S, Jernberg C, Jansson JK, Edlund C. Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes. J Antimicrob Chemother. 2006 Dec; 58(6): 1160–1167. https://doi.org/10.1093/jac/dkl420
- Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012 Sep;489(7415):220–230. https://doi.org/10.1038/nature11550
- Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, Buffet R, Bandinelli PA. NSCLC immunotherapy efficacy and antibiotic use: A systematic review and meta-analysis. J Thorac Oncol. 2020 Jul;15(7):1147–1159. https://doi.org/10.1016/j.jtho.2020.03.002
- Majeed U, Zhou K, Heng F, Seegobin K, Zhao Y, Manochakian R, Lou Y. P13.01 Use of antibiotics is associated with an increase in immunotherapy related adverse effects in patients with non-small cell lung cancer. J Thorac Oncol. 2021 Oct;16(10):S1010. https://doi.org/10.1016/j.jtho.2021.08.330
- Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 Jan; 359(6371):104–108. https://doi.org/10.1126/science.aao3290
- Mayo Clinic. Antibiotics: Are you misusing them? [Internet]. Rochester (USA): Mayo Foundation for Medical Education and Research; 2023 [cited 2023 May 5]. Available from https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/antibiotics/art-20045720
- Nyein AF, Bari S, Hogue S, Zhao Y, Maller B, Sha S, Gomez MF, Rollison DE, Robinson LA. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. BMC Cancer. 2022 Jan ;22(1):101. https://doi.org/10.1186/s12885-022-09210-2
- Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer. 2021 May;149:73–81. https://doi.org/10.1016/j.ejca.2021.02.040
- Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, Hansen TH, Liang S, Feng Q, Zhang C, et al Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018 Nov;3(11):1255–1265. https://doi.org/10.1038/s41564-018-0257-9
- Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Oggionni E, Abeni C, Hahne JC, Tomasello G, et al. Use of antibiotics and risk of cancer: A systematic review and meta-analysis of observational studies. Cancers. 2019 Aug;11(8):1174. https://doi.org/10.3390/cancers11081174
- Pierrard J, Seront E. Impact of the gut microbiome on immune checkpoint inhibitor efficacy – a systematic review. Curr Oncol. 2019 Dec;26(6):395–403. https://doi.org/10.3747/co.26.5177
- Ramírez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, Gálvez EM. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy. Trends Cancer. 2020 Feb;6(2): 86–97. https://doi.org/10.1016/j.trecan.2019.12.007
- Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Rang and Dale’s pharmacology, 9th ed. Edinburgh (UK): Elsevier. p. 673.
- Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Montagna ES, Ungaro V, Lorusso M, Palmiotti G. Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: A systematic review and meta-analysis. Cancers. 2022 Mar;14(6):1404. https://doi.org/10.3390/cancers14061404
- Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018b Jun;15(6): 382–396. https://doi.org/10.1038/S41571-018-0006-2
- Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018a Jan;359(6371):91–97. https://doi.org/10.1126/science.aan3706
- Ruiz-Patiño A, Barrón F, Cardona AF, Corrales L, Mas L, Martín C, Zatarain-Barrón ZL, Recondo G, Ricaurte L, Rojas L, et al.; CLICaP. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP). Thorac Cancer. 2020 Sep;11(9):2552–2560. https://doi.org/10.1111/1759-7714.13573
- Santacroce L, Charitos IA, Ballini A, Inchingolo F, Luperto P, De Nitto E, Topi S. The Human respiratory system and its microbiome at a glimpse. Biology. 2020 Oct;9(10):318. https://doi.org/10.3390/biology9100318
- Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer. Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1563–1579. https://doi.org/10.1158/1055-9965.EPI-19-0221
- Schett A, Rothschild SI, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol. 2020 Jan;85(1):121–131. https://doi.org/10.1007/s00280-019-03993-1
- Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, Kurata S. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int. 2003 Feb; 45(1): 86–90. https://doi.org/10.1046/j.1442-200X.2003.01671.x
- Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov;350(6264):1084–1089. https://doi.org/10.1126/science.aac4255
- Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001 Sep; 1(2):101–114. https://doi.org/10.1016/S1473-3099(01)00066-4
- Thomas S. Antimicrobial resistance: Global challenges and future interventions. Singapore: Springer Singapore; 2020. https://doi.org/10.1007/978-981-15-3658-8
- Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, Jodai T, Akaike K, Ishizuka S, Saeki S, et al. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol Res. 2020 Oct;8(10):1236–1242. https://doi.org/10.1158/2326-6066.CIR-20-0051
- Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. JAMA. 2004 Feb;291(7):827–835. https://doi.org/10.1001/jama.291.7.827
- Weinberger SE, Cockrill BA, Mandel J. 20 – Lung cancer: Etiologic and pathologic aspects. In: Principles of pulmonary medicine, 7th ed. Philadelphia (USA): Elsevier; 2019. p. 263. https://doi.org/10.1016/B978-0-323-52371-4.00023-4
- WHO. Antibiotic resistance [Internet]. Geneva (Switzerland): World Health Organization; 2023 [cited 2023 April 30]. Available from https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
- Wu X, Li F, Wang X, Li C, Meng Q, Wang C, Huang J, Chen S, Zhu Z. Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism. Biochem Biophys Res Commun. 2018 Jan;495(1):267–272. https://doi.org/10.1016/j.bbrc.2017.10.136
- You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006 Jul;98(14):974–983. https://doi.org/10.1093/jnci/djj264
- Zhang H, García Rodríguez LA, Hernández-Díaz S. Antibiotic use and the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1308–1315. https://doi.org/10.1158/1055-9965.EPI-07-2817
- Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell. 2016 Apr;165(2):276–287. https://doi.org/10.1016/j.cell.2016.03.001